{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:04:33Z","timestamp":1790715873963,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106914","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:10:54Z","timestamp":1787238654000},"page":"106914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9823","authenticated-orcid":false,"given":"Gili","family":"Kenet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-7489","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Berrueco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-5565","authenticated-orcid":false,"given":"Paula","family":"Kj\u00f6llerstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6939-3047","authenticated-orcid":false,"given":"Matteo","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-5641","authenticated-orcid":false,"given":"Nita","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"P\u00e1ramo Florencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Jay","family":"Thaung Zaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-1763","authenticated-orcid":false,"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.rpth.2026.106914_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O\u2019Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"6 Suppl 4","key":"10.1016\/j.rpth.2026.106914_bib3","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/j.amepre.2011.09.017","article-title":"Physical functioning in boys with hemophilia in the U.S","volume":"41","author":"Monahan","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.rpth.2026.106914_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2516.2010.02400.x","article-title":"The longitudinal effect of body adiposity on joint mobility in young males with haemophilia A","volume":"17","author":"Soucie","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/hae.12108","article-title":"Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia","volume":"19","author":"Bladen","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106914_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10245330701383700","article-title":"Evaluation of bone mineral density in children with hemophilia: Mansoura University children hospital (MUCH) experience, Mansoura, Egypt","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.rpth.2026.106914_bib8","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1007\/s12325-024-02956-0","article-title":"Clinical and humanistic burden of non-inhibitor haemophilia A in five European Countries: insights from the CHESS II study","volume":"41","author":"Ferri Grazzi","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106914_bib9","article-title":"Low bone mineral density in hemophiliacs","volume":"9","author":"Gebetsberger","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.rpth.2026.106914_bib10","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1182\/blood.2021013536","article-title":"Can we do something about ICH in hemophilia?","volume":"138","author":"Young","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106914_bib11","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.2021011849","article-title":"Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis","volume":"138","author":"Zwagemaker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106914_bib12","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103188","article-title":"More real-world evidence on the impact of emicizumab","volume":"9","author":"Teitel","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib14","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-015-0451-5","article-title":"New and emerging agents for the treatment of hemophilia: focus on extended half-life recombinant clotting proteins","volume":"75","author":"Ragni","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.rpth.2026.106914_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2516.2003.00840.x","article-title":"Central venous access devices in haemophilia","volume":"10","author":"Valentino","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib16","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/hae.13404","article-title":"Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals","volume":"24","author":"Buckley","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00247-020-04668-3","article-title":"Implantable venous access devices in children with severe hemophilia: a tertiary pediatric institutional experience","volume":"50","author":"Bedoya","year":"2020","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.rpth.2026.106914_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"issue":"Suppl 3","key":"10.1016\/j.rpth.2026.106914_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"Mancuso","year":"2024","journal-title":"Haemophilia"},{"issue":"Suppl 4","key":"10.1016\/j.rpth.2026.106914_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106914_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0044-1796651","article-title":"Non-factor therapies for hemophilia: achievements and perspectives","volume":"51","author":"Jim\u00e9nez-Yuste","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106914_bib23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/hae.14183","article-title":"Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors\u2014results from the HAVEN 2 study","volume":"26","author":"Mancuso","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib24","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106914_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/hae.14757","article-title":"Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences","volume":"29","author":"Kruis","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib27","unstructured":"Chenuel C, Delienne S, FIDEL\u2019HEM. PO352 therapeutic education for patients treated with Emicizumab in France. Presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2026 congress; Dublin, Ireland."},{"key":"10.1016\/j.rpth.2026.106914_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100087","article-title":"The dosing conundrum of emicizumab: to waste product or not?","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/13696998.2022.2115777","article-title":"Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe","volume":"25","author":"Mancuso","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.rpth.2026.106914_bib30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107162","article-title":"Model-informed drug development of Mim8\u2014a next-generation bispecific antibody for treatment of haemophilia A","volume":"212","author":"Kreilgaard","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.rpth.2026.106914_bib55","series-title":"Poster PO108 presented at: 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)","article-title":"Expedited learning and enhanced usability of a pre-filled Mim8 pen-injector for the management of haemophilia A","author":"Shastri","year":"2025"},{"key":"10.1016\/j.rpth.2026.106914_bib32","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2517384","article-title":"Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors","volume":"394","author":"Mancuso","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106914_bib33","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.rpth.2026.106914_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hae.15102","article-title":"Development and validation of the Child Hemophilia Treatment Experience Measure: a new observer-reported outcome measure","volume":"31","author":"Brod","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"key":"10.1016\/j.rpth.2026.106914_bib39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2026.106914_bib40","first-page":"45","article-title":"ICH harmonized tripartite guideline: guideline for good clinical practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.rpth.2026.106914_bib41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.rpth.2026.106914_bib42","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106914_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1932296817735121","article-title":"Impact of injection speed, volume, and site on pain sensation","volume":"12","author":"Zijlstra","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.rpth.2026.106914_bib44","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtha.2023.03.007","article-title":"In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays","volume":"21","author":"Lund","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-018-0929-9","article-title":"Inhibitor clinical burden of disease: a comparative analysis of the CHESS data","volume":"13","author":"Oladapo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2026.106914_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/20551029211039920","article-title":"It\u2019s difficult to say no: development of a parenting booklet about physical activity restrictions and recommendations in pediatric hemophilia","volume":"8","author":"B\u00e9rub\u00e9","year":"2021","journal-title":"Health Psychol Open"},{"key":"10.1016\/j.rpth.2026.106914_bib47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-0038-1648230","article-title":"Treatment regimens with bypassing agents in patients with hemophilia a and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE)","volume":"44","author":"Coppola","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106914_bib48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib49","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106914_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106914_bib57","article-title":"Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER","volume":"17","author":"Matsushita","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106914_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12782","article-title":"Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3","volume":"6","author":"Callaghan","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106914_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hae.14928","article-title":"Patient and caregiver preferences for haemophilia treatments: a discrete-choice experiment","volume":"30","author":"Garcia","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib53","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1111\/hae.14185","article-title":"Assessing patient and caregiver preferences for treatment of haemophilia A: a discrete choice experiment","volume":"27","author":"Benton","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106914_bib54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:06:58Z","timestamp":1790712418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035727"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106914","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106914"}}